← Back to Clinical Trials
Recruiting NCT06476977

NCT06476977 Intrasynovial Digital Anesthesia in Trigger Finger

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06476977
Status Recruiting
Phase
Sponsor Kevin Zuo
Condition Trigger Finger Disorder
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-07-03
Primary Completion 2026-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Dorsal webspace combined corticosteroid and anesthetic injectionPalmar combined corticosteroid and anesthetic injection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-07-03 with a primary completion date of 2026-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Trigger finger is a common disease of the hand involving swelling and inflammation of the tendon which flexes a finger, causing catching, locking, and/or pain. Trigger finger is typically treated by hand surgeons with a steroid injection through the front/palm side of the hand into the area near the tendon (i.e., at the base of the affected finger). This steroid injection is often combined with a local anesthetic (numbing agent) to help reduce short-term pain from the injection. However, the front/palm side of the hand is known to be very sensitive, and the steroid injection can be quite painful as the needle pierces the front/palm skin. To reduce the pain of steroid injections for trigger finger, a different approach involves performing the injection from the back/dorsal side of the hand, which is thought to be less sensitive (and therefore less painful) than the front/palm side of the hand. This technique is sometimes used and has been previously studied, but it is not clear if it can offer less injection-related pain than standard treatment. Accordingly, this study will be comparing short-term injection-associated pain between front/palm side and back/dorsal side steroid injections for trigger finger. The study will also seek to understand what area of the hand is numbed by the anesthetic when doing a front/palm side injection versus a back/dorsal side injection of the hand. Overall, the investigators hypothesize that back/dorsal side injections will be less painful than front/palm side injections for trigger fingers and that the area of numbing from the anesthetic will be equivalent between both types of injections.

Eligibility Criteria

Inclusion Criteria: * Be 18 years of age or older * Have a diagnosis of trigger finger (can be any of the 5 digits) * Opting to receive a CSI for their triggering finger Exclusion Criteria: * Decline to obtain a CSI for trigger finger management * Receiving multiple CSI for trigger finger management at the appointment * Past CSI and/or surgery to the digit involved * Unable to communicate in English

Contact & Investigator

Central Contact

Kevin Zuo, MD, MASc

✉ kevin.zuo@uhn.ca

📞 416-603-5802

Principal Investigator

Kevin Zuo, MD, MASc

PRINCIPAL INVESTIGATOR

University Health Network, Toronto

Frequently Asked Questions

Who can join the NCT06476977 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Trigger Finger Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06476977 currently recruiting?

Yes, NCT06476977 is actively recruiting participants. Contact the research team at kevin.zuo@uhn.ca for enrollment information.

Where is the NCT06476977 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT06476977 clinical trial?

NCT06476977 is sponsored by Kevin Zuo. The principal investigator is Kevin Zuo, MD, MASc at University Health Network, Toronto. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology